Expert outlines sequencing strategies for relapsed/refractory multiple myeloma amid rise of T-cell redirecting therapies

Dr. Diana Cirstea, a specialist in multiple myeloma, explained how treatment sequencing is evolving for patients with relapsed or refractory disease. She highlighted that the growing availability of T-cell-redirecting agents is reshaping therapeutic pathways.

The discussion emphasized the need to balance efficacy, safety, and patient-specific factors when deciding the order of therapies. Dr. Cirstea noted that earlier use of certain immunotherapies may influence outcomes of later lines of treatment.

She also pointed out that ongoing clinical trials and real-world experience will be critical to refine sequencing recommendations. The insights aim to help clinicians optimize care for a complex patient population.